Endogenous Intoxication Syndrome in Patients with Diabetes Mellitus in Combination with Nonalcoholic Fatty Liver Disease

The progressive proliferation of diabetes mellitus is a real threat to the quality of life of patients, aggravating the condition of other organs and systems of the body, which requires attention not only of endocrinologists, but also of specialists of other specialties. The importance of clinicians is increasly attracted by the peculiarities of the clinical course of non-alcoholic fatty liver disease (NAFLD) in combination with diabetes mellitus (DM), causal relationships, structural changes in the organs of the hepatobiliary zone and pathways to therapeutic tactics. Metabolic disturbances accompanying diabetes are associated with the accumulation of pathologically high concentrations of carbohydrate and lipid metabolism products, intermediate metabolites and abnormal compounds: oxidized lipoproteins, glycosylated proteins, products of vital functions of hypoxic tissues, and the like. Their toxic properties can lead to depletion of the detoxifying system with the further development of endogenous intoxication (EI). Since one of the parts of the detoxifying system is the liver, it is interesting to study the presence of endotoxemia and its role in the course of NSCLC in patients with diabetes mellitus. Material and methods. While examining 66 patients with diabetes mellitus in combination with nonalcoholic fatty liver disease, endogenous intoxication syndrome was detected in 83.8% of patients with type I diabetes and 74.3% of patients with type II diabetes mellitus. In the examination of patients in Group I, diabetic microangiopathy, manifested by proliferative retinopathy and/ or nephropathy, was established in 80.6% of the cases, macroangiopathy – 32.3%, neuropathy – 67.7%. Results and discussion. Among patients in group ІІ, diabetic microangiopathy was observed in 62.9%, macrogangiopathy – 20.0%, neuropathy – in 62.9% of patients whose frequency was associated with the duration of diabetes mellitus (r = 0.51; p <0.04 ) The level of MSM in patients with Group I increased by 27.1% (p <0.001), MDA in the plasma – by 29.0% (p <0.01), in red blood cells – by 28.1% (p <0.001). Moreover, the increase in the level of MSM in plasma occurred with an increase in HbA1c (r = 0.68; p <0.001) and glycemia (r = 0.86; p <0.001). On the other hand, with the increase in the content of MSM, the incidence of retinopathy (r = 0.74; p <0.001) and neuropathy (r = 0.68; p <0.001) increased. It was with MSM in patients of this group that correlated the degree of liver fibrosis (r = 0.93; p <0.001). The content of MSM directly correlated plasma levels of MDA (r = 0.89; p <0.001) and erythrocytes (r = 0.86; p <0.001), which confirms its known role in the development of ES syndrome. In turn, the concentration of MDA in both plasma and erythrocytes increased with increasing glycemia (r = 0.77; p <0.001 and r = 0.86; p <0.001), and excessive accumulation of MDA in erythrocytes was more characteristic of patients with DD with unsatisfactory glycemic control (r = 0.65; p <0.007). The degree of liver fibrosis increased (r = 0.72; p <0.001) with increasing MDA, and the incidence of microangiopathy (r = 0.48; p <0.03) and neuropathy (r = 0.67; p <0.002) did the same. In patients of group II, the incidence of MSM occurred at 29.8% (p <0.001), MDA of the blood plasma – by 32.2% (p <0.001), MDA in erythrocytes by 21.4% (p <0.001).